AgenciesCentrum Broking has buy call on Abbott India with a target price of Rs 23100. The current market price of . is Rs 19616.8.
Abbott India Ltd., incorporated in the year 1944, is a Large Cap company (having a market cap of Rs 41757.96 Crore) operating in Pharmaceuticals sector.
Ltd. key Products/Revenue Segments include Injectables, Tablets, Liquids, Capsules, Service Income, Others, Ointments, Granules, Powder, Other Operating Revenue, Export Incentives, Scrap for the year ending 31-Mar-2022.
Financials
For the quarter ended 30-09-2022, the company reported a Standalone Total Income of Rs 1413.01 Crore, up 6.18 % from last quarter Total Income of Rs 1330.73 Crore and up 13.93 % from last year same quarter Total Income of Rs 1240.27 Crore. Company reported net profit after tax of Rs 265.52 Crore in latest quarter.
Investment Rationale
Abbott has expanded its key portfolios and introduced 10 new products in FY22, in therapeutic areas of Women’s Health, Gastroenterology, Central Nervous System, Multi-speciality and Vaccines. Having strong set of brands, with highest MR productivity among its domestic peers, and its ability to grow ahead of the market, backed by price increases and traction in new launches. Cash on books also may be utilized for M&A in consumer health and vaccine brands. The brokerage maintains BUY with a target price of Rs23,100 at 40x on Sep’24 EPS. The stock currently trades at 44x and 38x on EPS of Rs451 and 519.6 of FY23/24E respectively.
Promoter/FII Holdings
Promoters held 74.99 per cent stake in the company as of 30-Sep-2022, while FIIs owned 2.79 per cent, DIIs 7.83 per cent.
Abbott India Ltd., incorporated in the year 1944, is a Large Cap company (having a market cap of Rs 41757.96 Crore) operating in Pharmaceuticals sector.
Ltd. key Products/Revenue Segments include Injectables, Tablets, Liquids, Capsules, Service Income, Others, Ointments, Granules, Powder, Other Operating Revenue, Export Incentives, Scrap for the year ending 31-Mar-2022.
Financials
For the quarter ended 30-09-2022, the company reported a Standalone Total Income of Rs 1413.01 Crore, up 6.18 % from last quarter Total Income of Rs 1330.73 Crore and up 13.93 % from last year same quarter Total Income of Rs 1240.27 Crore. Company reported net profit after tax of Rs 265.52 Crore in latest quarter.
Investment Rationale
Abbott has expanded its key portfolios and introduced 10 new products in FY22, in therapeutic areas of Women’s Health, Gastroenterology, Central Nervous System, Multi-speciality and Vaccines. Having strong set of brands, with highest MR productivity among its domestic peers, and its ability to grow ahead of the market, backed by price increases and traction in new launches. Cash on books also may be utilized for M&A in consumer health and vaccine brands. The brokerage maintains BUY with a target price of Rs23,100 at 40x on Sep’24 EPS. The stock currently trades at 44x and 38x on EPS of Rs451 and 519.6 of FY23/24E respectively.
Promoter/FII Holdings
Promoters held 74.99 per cent stake in the company as of 30-Sep-2022, while FIIs owned 2.79 per cent, DIIs 7.83 per cent.
(Disclaimer: Recommendations given in this section or any reports attached herein are authored by an external party. Views expressed are that of the respective authors/entities. These do not represent the views of Economic Times (ET). ET does not guarantee, vouch for, endorse any of its contents and hereby disclaims all warranties, express or implied, relating to the same. Please consult your financial adviser and seek independent advice.
Read More News on
(What's moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.
Pick the best stocks for yourself
Powered by